RPAM
ADPT icon

Rhenman & Partners Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-720,000
Closed -$9.99M – 100
2026
Q1 		$9.99M Buy
720,000
+115,000
+19% +$1.83M 1.23% 31
2025
Q4 		$9.83M Buy
605,000
+110,000
+22% +$1.8M 0.92% 43
2025
Q3 		$7.41M Buy
+495,000
New +$6.03M 0.82% 43

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rhenman & Partners Asset Management's ADPT Position: Q2 2026 in Review

Rhenman & Partners Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2026, closing a stake of 720,000 shares — an estimated $9.99M sold.

Rhenman & Partners Asset Management first reported a position in ADPT in Q3 2025 and held it in 3 quarters. The position peaked at $9.99M in Q1 2026. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Rhenman & Partners Asset Management reported no remaining Adaptive Biotechnologies position as of Q2 2026 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 720,000 Adaptive Biotechnologies shares in Q2 2026, an estimated $9.99M.
  • Rhenman & Partners Asset Management first reported a position in Adaptive Biotechnologies in Q3 2025 and held it in 3 quarters.
  • Rhenman & Partners Asset Management's Adaptive Biotechnologies position peaked at $9.99M in Q1 2026.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.